Results 231 to 240 of about 596,620 (345)
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC), particularly oral squamous cell carcinoma (OSCC), is associated with poor survival despite therapeutic advances. Tertiary lymphoid structures (TLSs) are emerging components of the tumor microenvironment, but their prognostic significance in HNSCC remains unclear.
Everton Freitas de Morais +4 more
wiley +1 more source
Composite lymphoma composed of follicular lymphoma and nodal T-follicular helper cell lymphoma: report of 3 cases highlighting histopathologic zonation of each neoplastic component. [PDF]
Zhao Y +8 more
europepmc +1 more source
A graphical abstract recapping the different sources of dental, periodontal, and other oral‐derived mesenchymal stromal cells (MSCs) and their regenerative mechanisms and potentials. The review's article findings bridge fundamental biological science with translational advances, highlighting the significance of MSCs in craniofacial regenerative ...
Karim M. Fawzy El‐Sayed +6 more
wiley +1 more source
Clinical implications of endoscopic phenotypes in primary small intestinal lymphoma. [PDF]
Lee YJ.
europepmc +1 more source
Successful Multimodal Therapeutic Approach for CD30‐positive Folliculotropic Mycosis Fungoides
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Chiara L. Blomen +5 more
wiley +1 more source
CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study
ABSTRACT Objective This study evaluated the CD4+ T‐cell role in mediating post‐Rituximab Pemphigus vulgaris (PV) relapse, comparing CD4+ count and CD4+/CD20+ ratio between patients who achieved remission and those who relapsed. Methods The clinical course of 27 PV patients treated with Rituximab was evaluated after a 32‐month median follow‐up. CD4+ and
Simone Liguori +9 more
wiley +1 more source
Extranodal marginal zone lymphoma presenting as a paraspinal mass and pleural effusion. [PDF]
Cami B +5 more
europepmc +1 more source
ABSTRACT Recent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children ...
Maria Gnarra Buethe +2 more
wiley +1 more source

